Clinical Trial Update: A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, immunogenicity, and pharmacokinetics of RO7126209 given IV in healthy participants; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• RO7126209

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Alzheimers Disease | Phase 1 | Status: COMPLETED | Results posted: 2021-08-09